Sesen Bio Inc

Sesen Bio — Q3 2019 Earnings Presentation

66 slides from Sesen Bio's earnings presentation, Nov 8, 2019

  1. Slide 1: 3Q 2019 Business Update

    3Q 2019 Business Update November 12, 2019 NASDAQ SESN

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and Vicinium®, the possibility that the FDA may require a change in our registration strategy uncertainties. All statements, other than statements of historical facts, contained in this an

  3. Slide 3: Our Path Forward Starts with the Patient Journey

    BLOOD IN URINE OUR PATH FORWARD See PCP; therapeutic trial of antibiotics prescribed STARTS WITH THE Still see blood in urine See PATIENT JOURNEY blood in urine; try different antibiotic Confusion and concern on problem Begin tests Referred to Urologist Shock and st CT Scan emotional Preparing for 1

  4. Slide 4: Sesen Bio: Late-stage oncology company

    SESEN BIO A late-stage oncology company developing targeted fusion protein medicines OUR MISSION We are passionate in our commitment to save and improve the lives of patients OUR TEAM Talented, dedicated and experienced management Thomas Cannell, DVM Jeannick Cizeau, Ph.D. Erin Clark Monica Forbes P

  5. Slide 5: 2019 IR Presentations: Frequent, Transparent and Informative

    2019 IR Presentations: Frequent, Transparent and Informative Recent Presentation Date � Business Update January 3 � 4Q 2018 Business Update March 4 � 1Q 2019 Business Update May 13 � Regulatory Update June 10 � Canaccord Conference August 7 � H.C. Wainwright Conference September 10 � 3Q 2019 Busines

  6. Slide 6: 3Q 2019 Financial Results and 2019 Financial Outlook

    3Q 2019 Financial Results and 2019 Financial Outlook Cash position • Ending cash and cash equivalents of $57.9M as of September 30, 2019 • Sufficient cash to fund key strategic priorities into 4Q 2020 • VISTA trial • Tech transfer and supply chain build-out • Regulatory activities: BLA submission an

  7. Slide 7: Agenda

    AGENDA 1. Significant Unmet Medical Need 2. Highly Differentiated Product Candidate with a Dual Mechanism of Action 3. Clear Regulatory Path Forward 4. Compelling Clinical Data Set 5. Large Global Commercial Opportunity 6. Reliable and Inexpensive Manufacturing Process 7

  8. Slide 8: Significant Unmet Medical Need in NMIBC

    Significant Unmet Medical Need in NMIBC ~440,000 new cases each year globally1 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 Bladder cancer is the single most expensive ($4 billion/year) cancer to treat in the US 4 BCG SHORTAGE One of the worst patient exper

  9. Slide 9: Significant Unmet Medical Need in NMIBC

    Significant Unmet Medical Need in NMIBC Only 3 products have ever been approved by the FDA for NMIBC Product FDA Approval Additional Product Information Thiotepa 1959 Rarely used in current treatment regimens BCG* 1989 (Tice) Recommended first line treatment Valstar 1998 Used only when radical cyste

  10. Slide 10: Vicinium is Highly Differentiated and has a Dual Mechanism of Action

    Vicinium is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr

  11. Slide 11: Clear Regulatory Path Forward

    Clear Regulatory Path Forward Anticipated Events 2019 - FDA • Typ e C CM C M e e tin g � Regulatory Designations - FDA • Type B Clinical pre-BLA Meeting � � Fast Track • Type C Confirmatory Trial Meeting � � Accelerated Approval Pathway • Type B CMC pre-BLA Meeting (Dec 4, 2019) � Rolling Review • I

  12. Slide 12: November 4th Type C FDA meeting

    November 4th Type C FDA meeting We were successful in gaining alignment with the FDA on the design of our post-marketing confirmatory trial for Vicinium Key Elements The confirmatory trial will enroll BCG-refractory patients who received less-than-adequate BCG* • This represents a broader patient po

  13. Slide 13: Compelling Phase III Clinical Data Set

    Compelling Phase III Clinical Data Set Efficacy at 3 months • CIS: 40% complete response rate • Papillary: 71% recurrence-free rate Durable Efficacy • CIS: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment • Papillary:

  14. Slide 14: Large Global Commercial Opportunity

    Large Global Commercial Opportunity Compelling Physician Intent to Prescribe Data After reviewing the data, high-prescribing Substantial US opportunity and OUS potential of 2-3 times the US Urologists state they would prescribe Vicinium to Anticipated virtuous cycle of advocacy across physicians, pa

  15. Slide 15: Reliable and Inexpensive Manufacturing Process

    Reliable and Inexpensive Manufacturing Process Vicinium is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-good

  16. Slide 16: Summary

    Summary Unmet Medical Need Patients with BCG-unresponsive NMIBC lack safe, effective treatment options, and the BCG shortage is further complicating patient care Dual Mechanism of Action Vicinium is a differentiated product candidate that has a direct cancer cell killing effect that may stimulate th

  17. Slide 17: Appendix - Table of Contents

    Appendix - Table of Contents Section Slide number Patient Journey 18-19 Unmet Medical Need 20-24 Dual Mechanism of Action 25-27 Regulatory 28-32 Clinical Data 33-50 Commercial Opportunity 51-59 Manufacturing & Supply Chain 60-64 Intellectual Property 65-66 17

  18. Slide 18: Appendix: Patient Journey

    Appendix Patient Journey 18

  19. Slide 19: Patient surveys show bladder cancer experience is among the poorest

    Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who HadWho Experience % of Patients 20 10

  20. Slide 20: Appendix: Unmet Medical Need

    Appendix Unmet Medical Need 20

  21. Slide 21: Carcinoma in situ: the most difficult form of NMIBC to treat

    Carcinoma in situ: the most difficult form of NMIBC to treat Carcinoma in situ vs. Normal Bladder Lining: Clinical Trial Implications: • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two or more courses of BCG, which is the gold standard f

  22. Slide 22: Radical cystectomy remains recommended option after BCG failure

    Radical cystectomy remains recommended treatment option after BCG failure 60-70% lifetime risk of cystectomy associated with NMIBC1 • Long, complex surgical procedure (10+ hours) • Significant rates of morbidity (30-60% within 90 days) and mortality (2-9% within 6 months)2 – 64% complication rate wi

  23. Slide 23: Vicinium is cystectomy-sparing

    Our Phase III data suggests Vicinium is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: A Hero Organ Radical Cystectomy: Life-Altering Surgery � Self-controlled storage organ in � Often a 10 hour or longer surgery the body � In women, removal of the ent

  24. Slide 24: Latest global BCG shortage expected to last through 2019

    Latest global BCG shortage expected to last at least through remainder of 2019 2012 2013 2014 2015 2016 2017 2018 2019 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints o

  25. Slide 25: Appendix: Dual Mechanism of Action

    Appendix Dual Mechanism of Action 25

  26. Slide 26: Vicinium: Dual Mechanism of Action

    Vicinium: Dual Mechanism of Action Mechanism 1: Exotoxin A Payload Kills cell directly Non-cleavable Ligand-checkpoint peptide Linker Vicinium interaction deactivates Antibody Fragment anti-tumor response Checkpoint Vicinium selectively Vicinium does not induce expression T cells recognize targets E

  27. Slide 27: High somatic mutation rate in bladder cancer may lead to better response

    The high somatic mutation rate in bladder cancer may lead to a better response to agents such as Vicinium that may stimulate T cell-mediated immune activation driven by neoantigens 27 Adapted from Zahir et al. Nature Medicine, 2017

  28. Slide 28: Appendix: Regulatory

    Appendix Regulatory 28

  29. Slide 29: Program aligned with FDA guidance

    Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models � • Conduct nonclinical studies to demonstrate anti-tum

  30. Slide 30: Strong benefit-risk profile in Phase III Trial

    Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp

  31. Slide 31: 2019 Regulatory Update: FDA Face-to-Face Meetings for Vicinium

    2019 Regulatory Update: FDA Face-to-Face Meetings for Vicinium May 20th Type C Meeting: FDA Accepts Analytical Comparability Plan to Support the BLA and Commercialization of Vicinium • No additional clinical trials deemed necessary at this time, subject to final review of comparability data in the B

  32. Slide 32: Updated Phase III data basis for BLA submission

    Updated Phase III data will be the basis for the initiation of the BLA submission anticipated in 4Q 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submiss

  33. Slide 33: Appendix: Clinical Data

    Appendix Clinical Data 33

  34. Slide 34: Phase III Trial: Patient Demographics

    PIII Phase III Trial: Patient Demographics All Cohorts COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months months but ≤11 months of CIS) that were refractory of adequate BCG adequate BCG or recurred within 6 mo

  35. Slide 35: Totality of Phase III data suggest strong benefit-risk profile

    PIII We believe the totality of Phase III data suggest a strong benefit-risk profile All Cohorts Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95%

  36. Slide 36: Additional Vicinium Clinical Data: CIS Patients

    PII & PIII Additional Vicinium Clinical Data CIS Patients Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-mon

  37. Slide 37: Evaluable Patient Data Tables by Cohort for CIS

    PIII Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ CIS patients Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 1

  38. Slide 38: Complete Response Rate: CIS Patients

    PIII Complete Response Rate: We believe our 95% confidence interval rules out CIS Patients the CRR for Valstar and a clinically unmeaningful CRR Complete Response Rate 40% Legend: 39% 35% 95% CI 30% 28% Vicinium 25% 26% Duration of Response for patients with a CR at 6 months: 1 20% 19% Valstar: 13.5

  39. Slide 39: Complete and Partial Response in Phase II

    Complete and Partial Response: In our Phase II clinical trial, 83% of PII patients had a complete or partial response CIS Patients 3-Month Response 40% of patients had a complete response Start of Treatment with 43% of patients had a partial response Vicinium 17% of patients had no response *Note: D

  40. Slide 40: Duration of Response: 52% remained disease-free at 12 months

    Duration of Response: 52% of CIS patients who had a complete response at PIII 3 months remained disease-free for a total of 12 months after starting CIS Patients treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40

  41. Slide 41: Longer complete response, higher probability of remaining cancer-free

    Duration of Response: The longer you have a complete response, the PIII higher the probability of remaining cancer-free CIS Patients Probability of Maintaining Complete Response (CR) for at Each time point a CR is confirmed, the probability of Least One Additional Year* maintaining a CR increases 11

  42. Slide 42: Vicinium more efficacious in CIS patients treated with less BCG

    Duration of Response: Vicinium is generally more efficacious in CIS patients PIII treated with less BCG CIS Patients The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations ≥10 BCG instillations 80 X Censored 60 Median 40 20 % of Patients % of Pati

  43. Slide 43: Time to Disease Recurrence: Papillary

    Time to Disease Recurrence: For high-risk papillary patients who were PIII Papillary treated with Vicinium, 50% are disease-free at 1 year Patients Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored Free - 95% CI 60 50% 40 37% % of Pat

  44. Slide 44: Time to Cystectomy: All Cohorts

    Time to Cystectomy: >75% of patients remain cystectomy-free for at PIII All Cohorts least 2.5 years No patient on treatment progressed to metastatic disease 100 80 Free - 60 Median 40 Legend: KM Estimate 20 X Censored % of Patients Cystectomy 95% CI 0 0 3 6 9 12 15 18 21 24 27 30 33 Time on treatmen

  45. Slide 45: Time to Cystectomy: Responders vs non-responders

    Time to Cystectomy: Responders have an 88% probability of remaining PIII cystectomy-free 3 years after starting treatment All Cohorts The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 Free Statistically significant difference for - 80 responders vs. non-

  46. Slide 46: Time to Cystectomy: Responders 88% cystectomy-free at 3 years

    Time to Cystectomy: Responders have an 88% probability of remaining PIII cystectomy-free 3 years after starting treatment All Cohorts 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. • The average responder remains cystectomy-free for 1,035 days

  47. Slide 47: Key Survival Endpoints

    Key Survival Endpoints: Early survival data are encouraging regarding PIII health outcomes for patients treated with Vicinium All Cohorts Progression-Free Survival Time Point (Evaluable Patients) Progression-Free Survival (95% CI) 6-months (52) 99% (97%-100%) 12-months (25) 96% (90%-100%) 18-months

  48. Slide 48: Safety and Tolerability

    Safety and Tolerability: Our Phase II and Phase III clinical trials are highly PII & PIII All Cohorts consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Tre a tm e n t-rel

  49. Slide 49: Safety and Tolerability: adverse events

    Phase III Phase trial Safety and Tolerability: Mean (range8.1 0 AEs patients:for all Note: 2 Datacohortsfrom all1, of consist& patients (n=133). 3 - 54), Mean treatment Mean AEs/patient 10 0 2 4 6 8 No ageNo The The average patient in the VISTA trial was ~74 years old 9.0 - related AEs for all patie

  50. Slide 50: Pipeline of Targeted Therapies

    Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicinium in combination with checkpoint inhibitors. Vicinium in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 study run by the National Cancer Institute. We have defe

  51. Slide 51: Appendix: Commercial Opportunity

    Appendix Commercial Opportunity 51

  52. Slide 52: Virtuous Cycle of advocacy

    Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo

  53. Slide 53: Key drivers of physician intent to prescribe

    Safety, MOA and efficacy are all key drivers in intent to prescribe for high- prescribing Urologists Physician Intent to Prescribe Key Drivers of Physician Intent to Prescribe After reviewing the data, high-prescribing Urologists state they would prescribe Vicinium to 10 8.8 9 8.6 8.5 8 Would 7 Pres

  54. Slide 54: High-prescribing Urologists recognize value across safety, MOA and efficacy

    High-prescribing Urologists recognize the significant value across safety, MOA and efficacy “This is another bladder intravesical treatment available with an even lower risk of side effects than BCG and has a greater ability to prevent recurrence.” Safety & Tolerability “…the fact that it is specifi

  55. Slide 55: Vicinium potential to provide continuity of care

    Vicinium has the potential to provide continuity of care for patients with NMIBC Tre a tm e n t w ith Tre a tm e n t w ith >90% of high-prescribing Urologists state Tre a tm e n t P rotocol BCG Vicinium that Vicinium would be very easy to integrate into their practice.* Directed by Urologist 9% Admi

  56. Slide 56: Addressable Market (US)

    Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~50% - 90% of BCG treatments fail or disea

  57. Slide 57: Pricing and Reimbursement (US)

    Pricing and Reimbursement (US) Price Reference Payer Management Responses (Annual Cost)1 to Pricing2 100% $200K CI 3 Price Range of Checkpoint CI 2 Inhibitors (CIs) for CI 1 Urothelial Carcinoma $150K 50% Proportion Payers of Proportion $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA

  58. Slide 58: OUS opportunity 2-3 times larger than US

    We estimate the OUS opportunity for Vicinium is 2-3 times larger than the US Geography Est. Incidence Relative to U.S.1 Est. Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not

  59. Slide 59: Only ~1,500 Urologists account for bulk of NMIBC treatment

    Only ~1,500 Urologists account for the bulk of NMIBC treatment and are concentrated in group practices allowing for a very efficient commercial model ~60% of Urology practices have ≥5 Urologists1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients 50% % of Patients of % 40%

  60. Slide 60: Appendix: Manufacturing & Supply Chain

    Appendix Manufacturing & Supply Chain 60

  61. Slide 61: Reliable and Inexpensive Manufacturing Process

    Reliable and Inexpensive Manufacturing Process 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ IMAC

  62. Slide 62: Experienced partners for global manufacturing and supply

    We have experienced partners for the global manufacturing and supply of Vicinium � Licensed for commercial production of 8 approved products � 25+ years developing and manufacturing biologics � 310+ protein-based therapeutics in development and/or manufacturing � Proven track record with FDA and wor

  63. Slide 63: Comparability Strategy accepted by the FDA

    The Comparability Strategy for Vicinium has been accepted by the FDA* Guidance “If a manufacturer can provide assurance of comparability through analytical studies alone, nonclinical or clinical studies with the post-change product are not warranted.”1 Sesen’s analytical comparability plan is compri

  64. Slide 64: Vicinium manufacturing much less complicated than ADCs

    The Vicinium manufacturing process is much less complicated than that for ADCs Vicinium cGMP manufacturing process producing a single fusion protein � Inexpensive � Reliable � Simple (linear) QA QA Purification Release Fill/Finish Release Bioreactor (Generates Drug (Generates Drug Market Substance)

  65. Slide 65: Appendix: Intellectual Property

    Appendix Intellectual Property 65

  66. Slide 66: Vicinium Patent Life

    Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 20

Sesen Bio — Q3 2019 Earnings Presentation on 6ix